ausblenden:
Schlagwörter:
MILD COGNITIVE IMPAIRMENT; LONG-TERM POTENTIATION; ALZHEIMERS-DISEASE;
AMYLOID-BETA; MOUSE MODELS; NEURONAL-ACTIVITY; IN-VIVO; PROTEIN;
PATHOLOGY; IMMUNIZATIONNeurosciences & Neurology; tau; amyloid beta-peptides; hippocampus; hyperexcitation; Dementia;
Zusammenfassung:
Hippocampal hyperactivity, ascribed to amyloid beta (A beta)-induced imbalances in neural excitation and inhibition, is found in patients with mild cognitive impairment, a prodromal stage of Alzheimer's disease (AD). To better understand the relationship between hippocampal hyperactivity and the molecular triggers of behavioral impairments in AD, we used Mn-enhanced MRI (MEMRI) to assess neuronal activity after subjecting mice to a task requiring spatial learning and memory. Depletion of endogenous tau in an amyloid precursor protein (APP) transgenic (J20) mouse line was shown to ameliorate hippocampal hyperactivity in J20 animals, tau depletion failed to reverse memory deficits associated with APP/A beta overproduction. On the other hand, deletion of tau alleviated the hyperlocomotion displayed by APP transgenics, suggesting that the functional effects of A beta-tau interactions reflect the temporal appearance of these molecules in individual brain areas.
